Aspen Grove Capital’s ResMed RMD Stock Holding History

Aspen Grove Capital’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,345	Closed	-$280K	–	173
2022 Q4	$280K	Buy	+1,345	New	+$296K	0.13%	114

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Aspen Grove Capital's RMD Position: Q1 2023 in Review

Aspen Grove Capital sold out of ResMed (RMD) in Q1 2023, closing a stake of 1,345 shares — an estimated $280K sold.

Aspen Grove Capital first reported a position in RMD in Q4 2022 and held it in 1 quarter. The position peaked at $280K in Q4 2022. 676 funds tracked by Wall St. Rank hold RMD as of Q1 2023.

Aspen Grove Capital reported no remaining ResMed position as of Q1 2023 after selling out during the quarter.
Aspen Grove Capital sold 1,345 ResMed shares in Q1 2023, an estimated $280K.
Aspen Grove Capital first reported a position in ResMed in Q4 2022 and held it in 1 quarter.
Aspen Grove Capital's ResMed position peaked at $280K in Q4 2022.
676 funds tracked by Wall St. Rank held ResMed as of Q1 2023.

Based on Aspen Grove Capital's 13F filing for Q1 2023, filed 15 May 2023.